ICON at a glance
Delivering successful outcomes across the clinical development lifecycle
ICON is the world’s leading contract research organisation (CRO), powered by Healthcare Intelligence, that integrates experience, expertise, cutting-edge technology and AI, and data to deliver exceptional outcomes.
In 2024, ICON supported:
-
1,465
Studies -
47,852
Patients
-
406
Customers -
18
Drug Approvals
Examples of recent notable projects include the execution of an anthrax vaccine clinical trial for the US Biomedical Advanced Research and Development Authority and a strategic partnership with LEO Pharma to improve the lives of dermatology patients.
ICON has a strong track record of growth. Highlights of the reported financial results for the full year 2024 include:
- Full year revenue of $8,281.7 million representing a year on year increase of 2.0% on a reported and constant currency basis.
- Full year net business wins of $9,974 million; a net book to bill of 1.20.
- Full year adjusted EBITDA was $1,735.8 million or 21.0% of revenue, a year on year increase of 2.5%.
- Net debt balance of $2.9 billion at December 31, 2024 with net debt to adjusted EBITDA ratio of 1.7x.
ICON has the scale, technology and data analytics to become the healthcare intelligence partner of choice through differentiated solutions and performance. ICON is:
- World leader in full-service phase 2/3 clinical research
- World leader for biotechnology sponsors
- World leader in functional services provision (FSP)
- Global number 2 in early phase clinical research
- Global number 2 in late phase clinical research and real-world evidence
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality — backed by our global team of experts with extensive experience across a broad range of therapeutic areas.
Today, ICON employees over 41,100 professionals across more than 55 countries, contributing to the success of our customers across a diverse range of therapeutic areas. From small local clinical trials to large global programs, we provide tailored services across the entire lifecycle of product development and commercialisation.
With a global reach, we offer comprehensive capabilities across phase 1-4 trials, with deep expertise in complex trials that require specialised knowledge and precision.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
ICON in Asia Pacific
As a leading CRO with a presence in Asia Pacific since 1995, local know-how is our speciality.
ICON in Latin America
As a leading CRO with a presence in Latin and Central America since 1998, we have local know-how and site relationships.